The power of ideas through the development of innovative research tools
News
- Medicago announces the development of a vaccine for rabies
- Medicago announces a collaboration with the French organization Cellectis
- Harnessing nanotechnology in the fight against cancer - Sylvain Martel
- CQDM will receive a grant from the BL-NCE to research better ways of developing and testing drugs that treat central nervous system diseases
- CQDM is proud to announce an investment of $1.5 M in two collaborative projects from the Québec/Ontario corridor
- CQDM announces the launching of the call for proposals of its 2012 Explore competition
- The CQDM and Univalor have announced a collaboration agreement
- Caprion Protéomique: la rentabilité avant les découvertes
- Philip Morris Investments B.V. exercises its pre-emptive right and invests $22.5 million in Medicago
- The CQDM is pleased to announce the recipients from its first Explore competition
- Selection of projects in the joint competition CQDM/Alsace BioValley 2011
- Eli Lilly Canada joins CQDM as a new pharma member
- CQDM welcomes two additional Pharma members, Boehringer Ingelheim and GlaxoSmithKline Inc.
- Merck Canada Invests $5 Million in Quebec Consortium for Drug Discovery to Support Biopharmaceutical Research
The Québec Consortium for Drug Discovery (CQDM) is a meeting ground for all stakeholders in biopharmaceutical research and whose principal mission is to fund research projects carried out in partnership between the academic and hospital milieus in the public sector and the pharmaceutical and biotechnology industries in the private sector.
An innovative Canadian initiative, CQDM has a twofold goal: to accelerate the drug discovery process and to develop safer and more effective drugs.
Established under an innovative public-private partnership model, CQDM puts the needs of the pharmaceutical industry at the very centre of its concerns.
2011 
